1 | | 素，已对公司防水产品价格进行了调整。 | | --- | --- | | | 3. 2025 年建筑涂料、工业涂料产品需求及价格变化趋势？ | | | 答：2025 年建筑涂料需求结构转型，存量房翻新重涂需求对 | | | 冲新房市场萎缩，其中功能性高端产品价格较为坚挺；工业涂料 | | | 总体稳健增长，也是整个涂料行业增长的重点，其中新能源、高 | | | 端装备领域需求旺盛，国产替代空间大，因此高技术壁垒的功能 | | | 性产品价格稳定，而低端防护领域价格竞争激烈。 | | | 4.请介绍公司国际化业务情况 | | | 答：目前公司已初步进入坦桑尼亚、乌兹别克斯坦和泰国市 | | | 场，计划通过由点到面的扩张方式，深入布局东南亚、中亚、非 | | | 洲、欧洲和地中海等关键区域。围绕"一体两翼"业务，公司也 | | | 将持续关注并寻求国际化整合机会。 | | | 5.请介绍公司未来的分红计划 | | | 答：公司注重与投资者共享发展成果，上市以来累计进行现 | | | 金分红 95.09 亿元，其中 2024 年现金分红比率提升至 40.07%。 | | | 未来，公司将努力创造更好业 ...

证券代码：688085 证券简称：三友医疗 公告编号：2026-007 上海三友医疗器械股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以上海三友医疗 器械股份有限公司（以下简称"公司"）2025年年度报告为准，提请投资者注意投资风险。 ■ 注： 1、报告期内，公司实施2024年度权益分配，向全体股东每10股以资本公积金转增2股，故对2024年基本 每股收益按照考虑实施2024年权益分配后的股本进行调整。 2、以上财务数据及指标以合并报表数据填列，但未经审计，最终结果以公司2025年年度报告为准。 3、本公告中除特别说明外，所有数值均保留2位小数，如有差异均为四舍五入原因造成。 二、经营业绩和财务状况情况说明 （一）报告期内公司的经营情况、财务状况及影响经营业绩的主要因素 报告期内，公司实现营业总收入54,279.25万元，同比增长19.66%；研发费用8,371.08万元，研发投入占 比15.42%；实 ...

2025年，公司在带量采购全面执行的压力下，利用自身创新疗法优势，不断进行新产品的开发和合作， 进一步丰富和增加公司的产品线，促进终端销售的持续扩展和渠道下沉，销售业绩稳定增长。同时，借 助全资子公司水木天蓬超声能量平台特别是超声骨刀和超声吸引设备等的创新技术，公司继续加强无源 和有源在疗法上的有机配合，为市场提供更多的一体化解决方案。2025年，超声骨刀业务在销售业绩和 净利润上均取得了快速的增长。公司国际化业务亦保持持续快速发展，2025年，公司控股公司 Implanet 实现营业收入1247.39万欧元，同比增长32.62%，其中美国市场表现优异，同比增长49.30%。但由于国 际化业务还处于销售推广和市场拓展前期，因此 Implanet 报告期内仍处于亏损状态，对公司2025年归 属于母公司的净利润的影响为-2600.00万元左右。 格隆汇2月26日丨三友医疗(688085.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入5.43亿 元，同比增长19.66%；研发费用8371.08万元，研发投入占比 15.42%；实现归属于母公司所有者的净利 润6328.95万元，同比增加451.85%； ...

Core Viewpoint - Spring Medical (01858) has announced a significant increase in its expected net profit for the fiscal year 2025, with projections indicating a rise of 96.01% to 130.41% year-on-year, driven by improvements in its core business and international expansion efforts [1][4]. Financial Performance - The company anticipates a net profit attributable to shareholders of between 245 million to 288 million yuan for 2025, and a non-recurring net profit of 230 million to 270 million yuan, reflecting increases of 96.01% to 130.41% and 142.80% to 185.11% respectively [1][4]. - In Q1 of the previous year, Spring Medical reported a revenue of 230 million yuan, marking a 3.6% increase, and a net profit of 58 million yuan, up 5.2% [7]. - By Q3 of the previous year, the company achieved a revenue of 756 million yuan, a year-on-year growth of 48.75%, and a net profit of 192 million yuan, a significant increase of 213.21% [7]. Market Reaction - Despite the positive earnings forecast, the market response has been muted, with the stock price declining by 2.87% the day after the announcement and continuing to fall, reaching a low of 13.47 HKD [4][10]. - The stock has experienced a maximum fluctuation of over 30% since hitting a peak of 20.49 HKD in early November [4][10]. Business Drivers - The growth in profits is attributed to the gradual release of growth potential following the inclusion of various product lines in centralized procurement, alongside the company's ongoing international development strategy [5][18]. - The overseas revenue contribution reached 40% in the first half of the previous year, indicating a strong international market presence [18]. Valuation - Following a three-month decline in stock price, Spring Medical's overall valuation has fallen below the industry average, with a current PE ratio of 19.12, compared to the industry average of 20.48 [11]. - The stock is considered undervalued, with a 6% lower PE ratio than its average over the past three months [11]. Investor Sentiment - Recent data indicates that the Hong Kong Stock Connect funds have shifted from being net buyers to net sellers of Spring Medical shares, with significant sell-offs observed [13][15]. - The holding ratio of Hong Kong Stock Connect funds decreased from a peak of 47.77% to 43.16%, reflecting a change in investment strategy towards trend-based trading [15].

Summary of Yili Co., Ltd. Conference Call Company Overview - **Company**: Yili Co., Ltd. - **Industry**: Dairy Products Key Points Revenue and Growth Expectations - Yili expects its ambient liquid milk business to achieve positive revenue growth by 2026, driven by the continued growth of yogurt, the launch of new white milk products, and the combination of cost-effective products with emerging channels [2][5] - If the industry experiences significant decline, Yili will prioritize profitability over revenue growth [2][5] Product Strategy - The company plans to optimize its product mix, increasing the share of adult nutrition products, deep processing products (like cheese), and international business to enhance overall gross margin and profitability [2][6] - Adult nutrition products are expected to maintain rapid growth, with plans to expand into non-powder products like protein powder and cautiously advance into functional health foods [2][8] Deep Processing Business - Yili aims for its deep processing business to reach a scale of 10 billion in the next five years, focusing on high-value products such as protein isolates and cheese [2][12] - The current deep processing business is at approximately 6 billion, with domestic sales around 2 billion and Westland contributing about 4 billion [12] Market Conditions and Pricing - Raw milk prices are expected to gradually rise in 2026, improving supply-demand dynamics, although small dairy enterprises may face increased costs [17] - Promotional activities are expected to decrease, positively impacting gross margins, but rising milk prices may have a negative effect, leading to stable overall gross margins [17] Inventory Management - Yili has actively reduced inventory levels since Q2 2024, with current dealer inventory around 20 days, and is focusing on natural sales rather than excessive stocking for the New Year [3] Channel Strategy - The company will adjust channel support policies based on market conditions, emphasizing cost efficiency [4] - Yili plans to replicate successful models in Southeast Asia and explore cold drink business opportunities in Africa, while collaborating with Ausnutria to share international supply chain resources [4][19] Emerging Channels - Emerging channels are generally profitable, with variations among them; membership stores show stronger profitability compared to bulk snack stores [23] - Yili aims to balance emerging and traditional channels, focusing on consumer engagement and customized products [24] Baby Formula Business - The 2025 fertility subsidy plan positively impacted the baby formula business, contributing to double-digit growth despite a declining birth rate [25] - Yili will continue to invest in customer acquisition strategies, even without the subsidy, to maintain growth in the baby formula segment [25] Capital Expenditure - Yili's capital expenditure for 2026 is projected at around 4 billion, with over 2 billion allocated for maintenance and the remainder for new projects [26] International Expansion - Yili plans to expand into other Southeast Asian countries and explore cold drink opportunities in Africa, adapting products to local climates [20] - The company will consider both self-built and acquisition strategies for market entry, depending on local conditions [21][22] Functional Health Products - Yili has introduced new functional products like protein powder and spore oil, targeting the aging population and leveraging e-commerce for initial sales [10] Collaboration with Tongrentang - The collaboration with Tongrentang on high-value products has shown positive results, contributing better margins [11] This summary encapsulates the key insights from Yili Co., Ltd.'s conference call, highlighting the company's strategic direction, market conditions, and growth initiatives.

摘要 康哲药业 2025 年实现正增长，毛利率和净利润改善，预计全年收入和 利润增长趋势明显。创新药商业化和国际化是未来主要增长驱动力，已 有五款创新药商业化，六款产品处于 NDA 阶段，数十项产品在临床阶段。 公司预计 2025-2027 年归母净利润分别为 16.5 亿元、19.6 亿元和 22.7 亿元，实现稳健增长。公司早期为 CSO 平台，后转型关注产品创 新、国际化及商业革新，2024 年进入创新产品商业化元年。 公司产品线包括存量国产品、独家或品牌产品及创新药。五款创新药自 2023 年陆续上市，预计 2025 年合计收入翻倍。研发管线丰富，包括 NDA 阶段及临床三期阶段的多项重磅新品。 心脑血管领域核心产品包括波依定、达力新、新活素等，总销售收入约 30 多亿元。维福瑞和维妥可表现突出，实现快速增长。德西杜斯塔片及 治疗 AD 等相关疾病的新疗法将丰富治疗方案。 创新药维福瑞用于透析后高磷血症，患者接受度高，副作用少，峰值销 售额有望超 20 亿元。注射用 Y3 治疗缺血性脑卒中，预防卒中后抑郁和 焦虑，预计峰值销售额可达 20-30 亿元。 Q&A 康哲药业在 2025 年上半年的业绩表现 ...

Group 1 - The core viewpoint of the article is that the company is leveraging its controlling stake in the French orthopedic company Implanet to expand its presence in the international high-end orthopedic market with innovative therapies and products [1] - The company has established a new international product brand based on Implanet, leading to sales growth in international markets, particularly in the United States [1] - The company plans to continue focusing on the high-end orthopedic markets in Europe and the United States, increasing sales investments to promote rapid development of its international business [1]

Core Viewpoint - The bond financing by securities firms remains robust entering 2026, with significant growth observed in 2025, driven by policy guidance and declining interest rates, making bond financing a key method for firms to supplement operating funds and refinance debts [1][3]. Group 1: Bond Financing Scale and Growth - In 2025, 77 securities firms issued a total of 1,004 domestic bonds, amounting to 1.89 trillion yuan, representing a year-on-year increase of nearly 40% [3]. - Major players in bond issuance included China Galaxy Securities, Guotai Junan, Huatai Securities, CITIC Securities, and others, with each issuing over 100 billion yuan [3]. - The increase in bond financing is attributed to the need for refinancing existing debts and supplementing operating funds amid a favorable policy and market environment [3]. Group 2: Types of Bonds and Financing Costs - In 2025, the issuance of short-term financing bonds totaled 326, amounting to 574.17 billion yuan, while regular corporate bonds accounted for 678 issues totaling 1.32 trillion yuan [4]. - The average coupon rate for outstanding securities company bonds was 1.97%, with some high-rated firms achieving rates as low as 1.54% [4]. - The average financing cost for short-term bonds was 1.76%, with a minimum of 1.52% and a maximum of 2.25% [4]. Group 3: Emerging Trends in Bond Issuance - The demand for perpetual subordinated bonds continued to grow, with 14 securities firms issuing a total of 66.8 billion yuan in 2025, marking an increase of over 40% from 2024 [7]. - The issuance of sci-tech bonds also saw rapid growth, totaling 83.44 billion yuan in 2025, reflecting a rising share of overall bond issuance [7]. - The average spread for bonds issued by securities firms was 43.27 basis points, while sci-tech bonds had a lower spread of 35.18 basis points, indicating a potential advantage for these types of bonds [7]. Group 4: International Financing Activities - In 2025, seven securities firms issued 30 offshore bonds, raising 4.703 billion USD, with growth exceeding 30% compared to 2024 [8]. - Notable examples include Tianfeng Securities planning to issue up to 960 million USD in offshore bonds to refinance existing debts [8]. - The trend of increasing offshore bond issuance is expected to continue as Chinese securities firms expand their international business [9].

Core Viewpoint - Company expects earnings per share for 2025 to be between 2.025 yuan and 2.3143 yuan, reflecting the impact of international trade fluctuations and domestic production challenges [1] Group 1: Performance Forecast - In 2025, the company's production and delivery were significantly affected in Q2 due to severe fluctuations in the international trade environment, although overseas capacity is expected to normalize later [2] - The company anticipates that its revenue will remain stable year-on-year, driven by new capacities in Vietnam and Thailand, as well as significant growth in new products, particularly electric tools [2] Group 2: Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 11.156 billion yuan, a year-on-year increase of 0.65%, and a net profit attributable to shareholders of 2.155 billion yuan, up 11.35% year-on-year [3] - The company’s gross profit margin stands at 33.08%, with investment income of 610 million yuan and financial expenses of -80.133 million yuan [3] Group 3: Future Outlook - The company has seen a year-on-year increase in new orders and plans to actively develop new businesses and products in 2026 to return to a reasonable growth range [2]

Core Viewpoint - The increasing openness of the capital market is driving Chinese securities firms to expand their international operations, with a focus on cross-border investment banking, wealth management, and financial technology to enhance cross-border capital management efficiency [1][2]. Group 1: Overseas Business Expansion - By 2025, at least 11 listed securities firms are expected to announce capital increases or the establishment of international subsidiaries, indicating a significant trend towards internationalization [1][2]. - In December 2025, China Merchants Securities announced a capital increase of up to 9 billion HKD for its subsidiary, aiming to enhance its financing capabilities and promote overseas investment [1]. - Shanxi Securities plans to increase capital by 1 billion HKD for its international subsidiary, which has seen a net profit of 47 million in the first nine months of the year, surpassing last year's total [1]. Group 2: Focus Areas for Capital Increase - The current round of capital increases by securities firms is primarily focused on capital intermediation and investment, with leading firms leveraging mature cross-border platforms to enhance capital returns [2]. - Smaller firms are concentrating on self-operated investments and wealth management, aiming to serve high-net-worth clients through the distribution of overseas products [2]. Group 3: International Business Development - Chinese securities firms are deepening their international business across investment banking, investment, and emerging sectors, playing a crucial role in the Hong Kong IPO market [3]. - As of December 15, 2025, CICC participated in 39 IPO projects, holding a market share of 16.53%, while CITIC Securities (Hong Kong) and Huatai Financial Holdings (Hong Kong) participated in 32 and 17 projects, respectively [3]. - The firms are also making strides in digital finance, with China Merchants Bank's subsidiary becoming the first Chinese bank-affiliated securities firm to obtain a virtual asset trading license in Hong Kong [3]. Group 4: Support for Enterprises Going Global - The China Securities Regulatory Commission is focusing on differentiated regulation to support high-quality institutions, which may enhance the profitability of firms with strong overseas business capabilities [5]. - CICC is supporting enterprises going global by providing cross-border M&A financing, overseas bond issuance, and connecting them with overseas investment institutions [5].